Verily is a health-technology and platform company purpose-built for precision health, combining deep clinical, regulatory, and technological expertise. Originally a moonshot project within Google X, it operates as a subsidiary of Alphabet Inc. and has a venture arm (Verily Ventures) that invests in early-stage life sciences and digital health companies.
36% of their portfolio is in Healthcare. Their most common stage is series-c (55% of deals). Average disclosed round size is $224.7M (across 10 rounds with reported amounts).
Portfolio
9
Fund Size
—
Top Stage
Series C
Last 12 Mo
0
Team
Bharat Rajagopal
Chief Revenue Officer
Laura O’Donnell
Chief Legal Officer
Scott Burke
Chief Technology Officer
Stephen Gillett
Chairman and CEO
Vindell Washington
Chief Physician Executive
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Nusano | Series C | $115M | Jan 2024 |
 Zephyr AI | Seed | $18.5M | Mar 2022 |
 Syllable | Series C | $40M | Jun 2021 |
 Genalyte | Series C | $50M | Jan 2021 |
 EQRx | Growth | $1.8B | Jan 2021 |
 Culture Biosciences | Series A | — | Mar 2020 |
 Ciitizen | Series A | $17M | Jan 2019 |
 Forward Health | Series C | $65M | Jan 2018 |
 Freenome | Series C | $65M | Mar 2017 |
| Genalyte | Series B | $36M | Nov 2016 |
| Syllable | Series C | $40M | — |
Top Co-Investors
Last updated: 20 October 2026